NCT01961115View on ClinicalTrials.gov

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 13, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

May 18, 2017

Conditions
Mucosal MelanomaRecurrent MelanomaRecurrent Uveal MelanomaStage IIIA Skin MelanomaStage IIIA Uveal MelanomaStage IIIB Skin MelanomaStage IIIB Uveal MelanomaStage IIIC Skin MelanomaStage IIIC Uveal MelanomaStage IV Skin MelanomaStage IV Uveal Melanoma
Interventions
DRUG

Epacadostat

Given PO

BIOLOGICAL

MELITAC 12.1 Peptide Vaccine

Given ID/SC

Trial Locations (4)

22908

University of Virginia Cancer Center, Charlottesville

27710

Duke University Medical Center, Durham

30322

Emory University/Winship Cancer Institute, Atlanta

44195

Cleveland Clinic Foundation, Cleveland

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Virginia

OTHER

lead

Fred Hutchinson Cancer Center

OTHER